Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Onco Targets Ther
2021 Jan 01;14:455-467. doi: 10.2147/OTT.S286751.
Show Gene links
Show Anatomy links
MicroRNA-1252-5p Associated with Extracellular Vesicles Enhances Bortezomib Sensitivity in Multiple Myeloma Cells by Targeting Heparanase.
Rodrigues-Junior DM
,
Pelarin MFA
,
Nader HB
,
Vettore AL
,
Pinhal MAS
.
???displayArticle.abstract???
INTRODUCTION: Multiple myeloma (MM) remains an incurable disease, and patient survival requires a better understanding of this malignancy's molecular aspects. Heparanase (HPSE) is highly expressed in aggressive MM cells and related to tumor growth, metastasis, and bortezomib (BTZ) resistance. Thus, targeting HPSE seems to be a promising approach for MM treatment, and because microRNAs (miRNAs) have emerged as potential regulators of HPSE expression, the use of extracellular vesicles (EVs) can allow the efficient delivery of therapeutic miRNAs.
METHODS: We used prediction algorithms to identify potential miRNAs that regulate negatively HPSE expression. RT-qPCR was performed to assess miRNAs and HPSE expression in MM lines (U266 and RPMI-8226). Synthetic miRNA mimics were electroporated in MM cells to understand the miRNA contribution in HPSE expression, glycosaminoglycans (GAGs) profile, cell proliferation, and cell death induced by BTZ. EVs derived from HEK293T cells were engineered with miRNAs to evaluate their therapeutic potential combined with BTZ.
RESULTS: It revealed a direct association between BTZ sensitivity, HPSE, and miR-1252-5p expressions. Moreover, overexpression of miR-1252-5p significantly reduced HPSE expression and HPSE enzymatic activity in MM cells. The higher level of miR-1252-5p was correlated with a reduction of cell viability and higher sensitivity to BTZ. Further, EVs carrying miR-1252-5p increased MM cells' sensitivity to BTZ treatment.
CONCLUSION: These results showed that miR-1252-5p could negatively regulate HPSE in MM, indicating the use of EVs carrying miR-1252-5p as a potential novel BTZ sensitization approach in MM cells.
Abdi,
Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis.
2017, Pubmed
Abdi,
Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis.
2017,
Pubmed
Ahmad,
MicroRNA theragnostics for the clinical management of multiple myeloma.
2014,
Pubmed
Bandari,
Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior.
2018,
Pubmed
Bouças,
Development of an enzyme-linked immunosorbent assay (ELISA)-like fluorescence assay to investigate the interactions of glycosaminoglycans to cells.
2008,
Pubmed
Desantis,
MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance.
2020,
Pubmed
El-Andaloussi,
Exosome-mediated delivery of siRNA in vitro and in vivo.
2012,
Pubmed
Fu,
miR-20b reduces 5-FU resistance by suppressing the ADAM9/EGFR signaling pathway in colon cancer.
2017,
Pubmed
Gargiulo,
Diagnostic and Therapeutic Potential of Extracellular Vesicles in B-Cell Malignancies.
2020,
Pubmed
Grosicki,
Bortezomib for the treatment of multiple myeloma.
2014,
Pubmed
He,
MicroRNAs: small RNAs with a big role in gene regulation.
2004,
Pubmed
Hostenkamp,
The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence.
2015,
Pubmed
Hulett,
Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis.
1999,
Pubmed
Johnsen,
Evaluation of electroporation-induced adverse effects on adipose-derived stem cell exosomes.
2016,
Pubmed
Juliano,
The delivery of therapeutic oligonucleotides.
2016,
Pubmed
Kelly,
High heparanase activity in multiple myeloma is associated with elevated microvessel density.
2003,
Pubmed
Kyle,
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.
2009,
Pubmed
Lewis,
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.
2005,
Pubmed
Liu,
Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity.
2013,
Pubmed
Lu,
MicroRNA expression profiles classify human cancers.
2005,
Pubmed
Mahtouk,
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.
2007,
Pubmed
Mateos,
Novel generation of agents with proven clinical activity in multiple myeloma.
2013,
Pubmed
Moloudizargari,
The emerging role of exosomes in multiple myeloma.
2019,
Pubmed
Moreau,
Proteasome inhibitors in multiple myeloma: 10 years later.
2012,
Pubmed
Palumbo,
Multiple myeloma.
2011,
Pubmed
Park,
MicroRNA-20b inhibits the proliferation, migration and invasion of bladder cancer EJ cells via the targeting of cell cycle regulation and Sp-1-mediated MMP-2 expression.
2015,
Pubmed
Pomatto,
Improved Loading of Plasma-Derived Extracellular Vesicles to Encapsulate Antitumor miRNAs.
2019,
Pubmed
Pulte,
Recent improvement in survival of patients with multiple myeloma: variation by ethnicity.
2014,
Pubmed
Ramani,
Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma.
2016,
Pubmed
Ramani,
Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype.
2016,
Pubmed
Ritchie,
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
2011,
Pubmed
Rodrigues-Junior,
Downregulation of DCC sensitizes multiple myeloma cells to bortezomib treatment.
2019,
Pubmed
,
Echinobase
Rodrigues-Junior,
Circulating extracellular vesicle-associated TGFβ3 modulates response to cytotoxic therapy in head and neck squamous cell carcinoma.
2019,
Pubmed
,
Echinobase
Röllig,
Multiple myeloma.
2015,
Pubmed
Sanderson,
Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis.
2004,
Pubmed
Sheng,
MicroRNA-429 decreases the invasion ability of gastric cancer cell line BGC-823 by downregulating the expression of heparanase.
2018,
Pubmed
Shi,
MicroRNA-1258: An invasion and metastasis regulator that targets heparanase in gastric cancer.
2017,
Pubmed
Tang,
The expression and clinical significance of microRNA-1258 and heparanase in human breast cancer.
2013,
Pubmed
Théry,
Isolation and characterization of exosomes from cell culture supernatants and biological fluids.
2006,
Pubmed
Tian,
MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2.
2019,
Pubmed
Tian,
Cinnamaldehyde induces cell apoptosis mediated by a novel circular RNA hsa_circ_0043256 in non-small cell lung cancer.
2017,
Pubmed
Tian,
CircABCB10 promotes nonsmall cell lung cancer cell proliferation and migration by regulating the miR-1252/FOXR2 axis.
2019,
Pubmed
Toyoshima,
Human heparanase. Purification, characterization, cloning, and expression.
1999,
Pubmed
Usman,
Efficient RNA drug delivery using red blood cell extracellular vesicles.
2018,
Pubmed
Valadi,
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.
2007,
Pubmed
Vlachos,
DIANA-miRPath v3.0: deciphering microRNA function with experimental support.
2015,
Pubmed
Wu,
MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4.
2020,
Pubmed
Yang,
Heparanase promotes the spontaneous metastasis of myeloma cells to bone.
2005,
Pubmed
Yuan,
miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
2019,
Pubmed
Zhang,
MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase.
2011,
Pubmed
Zhou,
Tumor‑suppressive miR‑299‑3p inhibits gastric cancer cell invasion by targeting heparanase.
2019,
Pubmed
Zhu,
Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells.
2017,
Pubmed